- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: LY-127809 | Permax®
pergolide is an approved drug (FDA (1988))
Compound class: Synthetic organic
Comment: Marketed formulations may contain pergolide mesylate (PubChem CID 47812).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.
|Summary of Clinical Use
|Used in the treatment of Parkinson's disease as an adjunctive to levodopa or carbidopa. For this indication the drug's primary molecular targets are the central dopamine receptors.
However, the drug's off-target agonist activity at 5-HT2B receptors appears to have been responsible for unacceptable levels of drug-induced cardiac valve damage  which lead to the drug's withdrawal from the US market in 2007.
|Mechanism Of Action and Pharmacodynamic Effects
|For an overview of the mechanism of action of pergolide, please follow the DrugBank link on the Summary tab of this ligand page.